Currier is an advisor to ViiV and wrote a commentary about one study on the drug in the New England Journal of Medicine.

柯瑞尔是ViiV公司的顾问，她在《新英格兰医学杂志》上为该药物的一项研究撰写了评论。

The first injectable PrEP was cabotegravir, made by ViiV Healthcare and approved by America's Food and Drug Administration (FDA) in 2021.

第一个可注射的 PrEP 是卡博特韦，由 ViiV Healthcare 生产， 并于 2021 年获得美国食品药品监督管理局 (FDA) 的批准。